Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
NewGam (current working title for a new IGIV formulation) is a newly developed human normal
immunoglobulin solution ready for intravenous administration (IGIV). This study will evaluate
the safety and efficacy of three different dosages of NewGam 10% in patients with Chronic
Inflammatory Demyelinating Polyradiculoneuropathy.